Related Experiment Video
Updated: Aug 17, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Quality control and stability study using HPTLC: applications to cyclophosphamide in various pharmaceutical products
Jérôme Bouligand1, Thomas Storme, Isabelle Laville
1Department of Clinical Pharmacy, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800 Villejuif, France.
Abstract:
Cyclophosphamide is an alkylating agent widely used from cancer chemotherapy to immunotherapy purposes. In paediatrics oncology, oral cyclophosphamide prescribed at low dosages for a long time treatment is currently investigated. This treatment is a putative well tolerated regimen for children treated for a wide variety of recurrent solid tumours. For these purposes, new oral formulations more convenient for children than cyclophosphamide 50mg tablets are needed. Thus, we present a rapid method for the assay of cyclophosphamide in various pharmaceutical preparations using high-performance thin-layer chromatography (HPTLC) and derivatization with phosphomolybdic acid. This method is accurate and precise and allows quantitation of cyclophosphamide in aqueous solutions from 400 to 1200 microg/mL. It is suitable for quantitation and stability studies of cyclophosphamide in pharmaceutical products, i.e. capsules and infusion bags prepared in a hospital pharmacy. According to pharmaceutical guidelines, we demonstrated that low dose cyclophosphamide capsules, extemporaneously prepared for children, are stable at least for 70 days.
More Related Videos
Related Concept Videos
Drug Product Stability
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Clinically Relevant Drug Product Specifications: Methods of Establishment
High-Performance Liquid Chromatography: Introduction
In HPLC, two phases play a critical role in the separation process:
Drug Dissolution: Requirements and Profile Comparison
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

